Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-10-2017 | Original Article

The potential of ²²³Ra and ¹⁸F-fluoride imaging to predict bone lesion response to treatment with ²²³Ra-dichloride in castration-resistant prostate cancer

Authors: Iain Murray, Sarah J. Chittenden, Ana M. Denis-Bacelar, Cecilia Hindorf, Christopher C. Parker, Sue Chua, Glenn D. Flux

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2017

Abstract

Purpose

The aims of this study were to calculate bone lesion absorbed doses resulting from a weight-based administration of ²²³Ra-dichloride, to assess the relationship between those doses and corresponding ¹⁸F-fluoride uptake and to assess the potential of quantitative ¹⁸F-fluoride imaging to predict response to treatment.

Methods

Five patients received two intravenous injections of ²²³Ra-dichloride, 6 weeks apart, at 110 kBq/kg whole-body weight. The biodistribution of ²²³Ra in metastatic lesions as a function of time after administration as well as associated lesion dosimetry were determined from serial ²²³Ra scans. PET/CT imaging using ¹⁸F-fluoride was performed prior to the first treatment (baseline), and at week 6 immediately before the second treatment and at week 12 after baseline.

Results

Absorbed doses to metastatic bone lesions ranged from 0.6 Gy to 44.1 Gy. For individual patients, there was an average factor difference of 5.3 (range 2.5–11.0) between the maximum and minimum lesion dose. A relationship between lesion-absorbed doses and serial changes in ¹⁸F-fluoride uptake was demonstrated (r² = 0.52). A log-linear relationship was demonstrated (r² = 0.77) between baseline measurements of ¹⁸F-fluoride uptake prior to ²²³Ra-dichloride therapy and changes in uptake 12 weeks after the first cycle of therapy. Correlations were also observed between both ²²³Ra and ¹⁸F-fluoride uptake in lesions (r = 0.75) as well as between ²²³Ra absorbed dose and ¹⁸F-fluoride uptake (r = 0.96).

Conclusions

There is both inter-patient and intra-patient heterogeneity of absorbed dose estimates to metastatic lesions. A relationship between ²²³Ra lesion absorbed dose and subsequent lesion response was observed. Analysis of this small group of patients suggests that baseline uptake of ¹⁸F-fluoride in bone metastases is significantly correlated with corresponding uptake of ²²³Ra, the associated ²²³Ra absorbed dose and subsequent lesion response to treatment.

Gartrell BA, Saad F. Managing bone metastases and reducing skeletal related events in prostate cancer. Nat rev Clin Oncol. 2014;11:335–45. doi:10.1038/nrclinonc.2014.70.CrossRefPubMed

Bodei L, Lam M, Chiesa C, Flux G, Brans B, Chiti A, et al. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl med Mol Imaging. 2008;35:1934–40. doi:10.1007/s00259-008-0841-y.CrossRefPubMed

Florimonte L, Dellavedova L, Maffioli LS. Radium-223 dichloride in clinical practice: a review. Eur J Nucl med Mol Imaging. 2016;43:1896–909. doi:10.1007/s00259-016-3386-5.CrossRefPubMed

Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, et al. A bone marrow toxicity model for Ra-223 alpha-emitter radiopharmaceutical therapy. Phys med Biol. 2012;57:3207–22. doi:10.1088/0031-9155/57/10/3207.CrossRefPubMedPubMedCentral

Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer res. 2005;11:4451–9. doi:10.1158/1078-0432.ccr-04-2244.CrossRefPubMed

Hindorf C, Chittenden S, Aksnes AK, Parker C, Flux GD. Quantitative imaging of Ra-223-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl med Commun. 2012;33:726–32.CrossRefPubMed

Takahashi A, Miwa K, Sasaki M, Baba S. A Monte Carlo study on (223)Ra imaging for unsealed radionuclide therapy. Med Phys. 2016;43:2965. doi:10.1118/1.4948682.CrossRefPubMed

Chittenden SJ, Hindorf C, Parker CC, Lewington VJ, Pratt BE, Johnson B, et al. A phase 1, open-label study of the Biodistribution, pharmacokinetics, and Dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases. J Nucl med. 2015;56:1304–9. doi:10.2967/jnumed.115.157123.CrossRefPubMed

Yoshida K, Kaneta T, Takano S, Sugiura M, Kawano T, Hino A, et al. Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases. Ann Nucl med. 2016;30:453–60. doi:10.1007/s12149-016-1093-8.CrossRefPubMedPubMedCentral

10.

Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of (2)(2)(3)Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl med Mol Imaging. 2013;40:1384–93. doi:10.1007/s00259-013-2427-6.CrossRefPubMedPubMedCentral

11.

Pacilio M, Ventroni G, De Vincentis G, Cassano B, Pellegrini R, Di Castro E, et al. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting Ra-dichloride. Eur J Nucl med Mol Imaging. 2015; doi:10.1007/s00259-015-3150-2.

12.

Nilsson S, Strang P, Aksnes AK, Franzen L, Olivier P, Pecking A, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48:678–86. doi:10.1016/j.ejca.2011.12.023.CrossRefPubMed

13.

Parker CC, Pascoe S, Chodacki A, O'Sullivan JM, Germa JR, O'Bryan-Tear CG, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63:189–97. doi:10.1016/j.eururo.2012.09.008.CrossRefPubMed

14.

Segall GM. PET/CT with sodium 18F-fluoride for management of patients with prostate cancer. J Nucl med. 2014;55:531–3. doi:10.2967/jnumed.113.133546.CrossRefPubMed

15.

Mick CG, James T, Hill JD, Williams P, Perry M. Molecular imaging in oncology: (18)F-sodium fluoride PET imaging of osseous metastatic disease. AJR am J Roentgenol. 2014;203:263–71. doi:10.2214/AJR.13.12158.CrossRefPubMed

16.

Piert M, Zittel TT, Becker GA, Jahn M, Stahlschmidt A, Maier G, et al. Assessment of porcine bone metabolism by dynamic [F-18]fluoride ion PET: correlation with bone histomorphometry. J Nucl med. 2001;42:1091–100.PubMed

17.

Neuman WF, Hursh JB, Boyd J, Hodge HC. On the mechanism of skeletal fixation of radium. Ann N Y Acad Sci. 1955;62:125–36. doi:10.1111/j.1749-6632.1955.tb35369.x.CrossRef

18.

Keightley J, Pearce A, Fenwick A, Collins S, Ferreira K, Johansson L. Standardisation of 223Ra by liquid scintillation counting techniques and comparison with secondary measurements. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for use in Agriculture, Industry and Medicine. 2014;95C:114–21. doi:10.1016/j.apradiso.2014.10.009.

19.

Zimmerman BE, Bergeron DE, Cessna JT, Fitzgerald R, Pibida L. Revision of the NIST standard for (223)Ra: new measurements and review of 2008 data. Journal of Research of the National Institute of Standards and Technology. 2015;120:37–57. doi:10.6028/jres.120.004.CrossRefPubMedPubMedCentral

20.

Cook GJR, Parker C, Chua S, Johnson B, Aksnes AK, Lewington VJ. F-18-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with Ra-223-chloride (Alpharadin). EJNMMI Res. 2011;1.

21.

Buijs WCAM, Siegel JA, Boerman OC, Corstens FHM. Absolute organ activity estimated by five different methods of background correction. J Nucl med. 1998;39:2167–72.PubMed

22.

Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl med. 1999;40:37s–61s.PubMed

23.

Hatt M, Cheze le Rest C, Turzo A, Roux C, Visvikis D. A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET. IEEE Trans med Imaging. 2009;28:881–93.CrossRefPubMedPubMedCentral

24.

Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294–310. doi:10.1097/00004032-200309000-00006.CrossRefPubMed

25.

Basic anatomical and physiological data: The skeleton. Annals of the ICRP. 1995;25:1–80. doi: 10.1016/S0146-6453(00)80004-4.

26.

Hindorf C. Dosimetry for radionuclide therapy with 223Ra-Cl2 with the biokinetics for the daughters measured separately. In preparation.

27.

Kessler RM, Ellis JR, Eden M. ANALYSIS OF EMISSION TOMOGRAPHIC SCAN DATA - LIMITATIONS IMPOSED BY RESOLUTION AND BACKGROUND. J Comput Assist Tomogr. 1984;8:514–22. doi:10.1097/00004728-198406000-00028.CrossRefPubMed

28.

BIPM, IEC, IFCC, ILAC, ISO, IUPAC, et al. Evaluation of measurement data - Guide to the expression of uncertainty in measurement. Jt Comm Guides Metrol (JCMG). 2008;101.

29.

Lin C, Bradshaw TJ, Perk TG, Harmon S, Eickhoff J, Jallow N, et al. Repeatability of quantitative 18F-NaF PET: a multicenter study. J Nucl med. 2016; doi:10.2967/jnumed.116.177295.

30.

Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney YY, et al. The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. J Nucl med. 2012;53:1175–84. doi:10.2967/jnumed.111.100883.CrossRefPubMedPubMedCentral

31.

Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl med. 2010;51:311–28. doi:10.2967/jnumed.108.058651.CrossRefPubMed

32.

Feinendegen LE, McClure JJ. Meeting report - alpha-emitters for medical therapy - workshop of the United States Department of Energy - Denver, Colorado, may 30-31, 1996. Radiat res. 1997;148:195–201. doi:10.2307/3579579.CrossRef

33.

Hatt M, Le Rest CC, Albarghach N, Pradier O, Visvikis D. PET functional volume delineation: a robustness and repeatability study. Eur J Nucl med Mol Imaging. 2011;38:663–72. doi:10.1007/s00259-010-1688-6.CrossRefPubMed

34.

Hatt M, Rest CC-L, Aboagye EO, Kenny LM, Rosso L, Turkheimer FE, et al. Reproducibility of (18)F-FDG and 3 '-Deoxy-3 '-(18)F-Fluorothymidine PET tumor volume measurements. J Nucl med. 2010;51:1368–76. doi:10.2967/jnumed.110.078501.CrossRefPubMed

35.

Kairemo K, Joensuu T. Radium-223-dichloride in castration resistant metastatic prostate cancer-preliminary results of the response evaluation using F-18-fluoride PET/CT. Diagnostics. 2015;5:413–27. doi:10.3390/diagnostics5040413.CrossRefPubMedPubMedCentral

Title: The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer
Authors: Iain Murray
Sarah J. Chittenden
Ana M. Denis-Bacelar
Cecilia Hindorf
Christopher C. Parker
Sue Chua
Glenn D. Flux
Publication date: 01-10-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-017-3744-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The potential of ²²³Ra and ¹⁸F-fluoride imaging to predict bone lesion response to treatment with ²²³Ra-dichloride in castration-resistant prostate cancer

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2017

The ninth international congress of the Croatian Society of Nuclear Medicine – Rovinj, May 04–07, 2017

Prognostic importance of lymph node-to-primary tumor standardized uptake value ratio in invasive squamous cell carcinoma of uterine cervix

Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer

Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of 18F-FDG PET

Response to the letter by Adams and Kwee, entitled: “Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma”

The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy